Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- James Lowder, MD
Astex Pharmaceuticals, Inc.
Study Chair - Mohammad Azab, MD
Astex Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alberta Hospital
Edmonton, Alberta, Canada
- Princess Margaret Cancer Center
Toronto, Ontario, Canada
- Sunnybrook Health Sciences Centre, Odette Cancer Centre
Toronto, Ontario, Canada
- Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
- Mayo Clinic
Phoenix, Arizona, United States
- University of Southern California
Los Angeles, California, United States
- University of Chicago
Chicago, Illinois, United States
- Horizon Oncology
Lafayette, Indiana, United States
- Johns Hopkins
Baltimore, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- John Theurer Cancer Center/ Hackensack University Medical Center
Hackensack, New Jersey, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York, United States
- Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States
- M. D. Anderson
Houston, Texas, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Oct 2014
- Primary completion
- 5 Jun 2018
- Completion
- 4 Dec 2019
- Last update posted
- 27 Aug 2024
- Registered enrollment
- 130
- Registry id
- NCT02103478
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.